相关临床试验
152
143 进行中
药物批准
1
批准总数
监管机构
1
监管机构数
成立时间
N/A
进行中（未招募）
142
93.4%
已完成
6
4.0%
尚未招募
1
0.7%
招募中
3
2.0%
- ChronicleBio appointed Dr. John Mumm, a three-decade immunology innovator and former Deka Biosciences CEO, as Chief Scientific Officer to lead its neuroimmune disease pipeline. - Mumm joins Head of Platform Dr. Yambazi Banda to build a multi-omic endotype framework integrating genomics, proteomics, and AI to stratify patients by disease mechanism. - The company targets historically neglected neuroimmune conditions including ME/CFS, Long COVID, and POTS, which affect millions of patients worldwide. - Mumm's track record includes advancing Deka Biosciences from inception to FDA-cleared Phase 1 trial within 18 months and co-founding ARMO BioSciences, acquired by Eli Lilly for $1.6 billion.
- Alethio Therapeutics announced ATX-011, a first-in-class, mutation-agnostic antibody targeting the $2 billion Essential Thrombocythemia market with potential to replace 50-year-old standard of care hydroxyurea. - The therapy demonstrated rapid platelet normalization within days in non-human primate models with zero myelosuppression and no safety signals, addressing limitations of current treatments. - The company appointed Steve R. Coats, PhD, as Chief Development Officer to advance ATX-011 toward IND submission in Q1 2027 and clinical proof-of-concept data by H1 2028. - ATX-011 targets the entire ET population regardless of mutation status, addressing an underserved market of over 140,000 US patients where 40-50% of current patients experience treatment resistance or intolerance.
- Immunocore announced that Dr. David Berman, Executive Vice President of Research and Development, will leave the company on February 27, 2026, to join a large commercial-stage biotech company. - The company will not seek a direct replacement for Dr. Berman and instead will streamline its R&D structure by promoting two existing leaders to Executive Vice President roles. - Dr. Mohammed Dar, current Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, will assume expanded oversight of clinical development and regulatory strategies. - The leadership transition comes as Immunocore continues to advance three ongoing Phase 3 trials and maintains its pipeline development across oncology, infectious diseases, and autoimmune therapeutic areas.
- Orum Therapeutics has appointed Dr. Dorin Toader as Head of Platform Technology to advance its degrader-antibody conjugate (DAC) platforms and expand therapeutic applications. - Dr. Toader brings over 27 years of drug discovery experience, including 15+ years in antibody-drug conjugates, having previously advanced multiple first-in-class ADC candidates into clinical development. - The appointment strengthens Orum's proprietary Dual-Precision Targeted Protein Degradation (TPD²) approach, which combines targeted protein degraders with antibody delivery mechanisms for cancer treatment. - Dr. Toader will lead innovation in payload design, conjugation technologies, and computational modeling to develop next-generation targeted degrader-antibody conjugates for various cancers and serious diseases.
- A groundbreaking NIH study demonstrates that a single dose of MEDI8852, a broadly neutralizing antibody developed by MedImmune/AstraZeneca, provides complete protection against H5N1 avian influenza in macaques. - The antibody targets a stable portion of the influenza virus protein, offering extended protection that could last weeks after administration, making it a promising preventive tool for potential H5N1 outbreaks. - All macaques pre-treated with MEDI8852 survived H5N1 exposure with minimal or no symptoms, while untreated control subjects developed severe or fatal illness.
• Aridis Pharmaceuticals has executed an agreement to sell AR-501, a therapeutic for chronic bacterial lung infections in cystic fibrosis, for $6.5 million plus royalties. • The company is in discussions for an investment to fund the final Phase 3 study of AR-301, an adjunctive treatment for Ventilator Associated Pneumonia (VAP). • A licensing dispute with MedImmune for AR-320, a VAP prevention candidate, remains unresolved, leading to the likely discontinuation of its Phase 3 trial.
• Over 50 companies are actively developing more than 50 therapeutic options for Respiratory Syncytial Virus (RSV) treatment, indicating a robust pipeline. • GSK's Arexvy vaccine demonstrated encouraging Phase III results, preventing lower respiratory tract disease (LRTD) in older adults across three RSV seasons. • Merck's clesrovimab showed positive topline results in a Phase IIb/III trial as a preventive treatment for RSV in infants, highlighting potential for vulnerable populations.
- The FDA has approved FluMist, a nasal spray flu vaccine, for self-administration, marking the first flu vaccine that can be administered at home. - FluMist is approved for individuals aged 2 to 49 and will be available through an online pharmacy with a prescription, starting next flu season. - The approval is based on studies showing that adults can safely and effectively administer the vaccine themselves or to children with proper instructions. - This new option aims to improve convenience, flexibility, and accessibility to seasonal influenza vaccination, potentially increasing vaccination rates.
• Sanofi announces major strategic shift, discontinuing diabetes and cardiovascular R&D while prioritizing six potentially transformative therapies and its successful Dupixent franchise. • The company's pipeline now features promising candidates including fitusiran for hemophilia, venglustat for rare diseases, and novel treatments for breast cancer and multiple sclerosis. • Strategic realignment expected to generate €2 billion in cost savings, enabling increased investment in pipeline development and wider profit margins.
- Merck & Co's $394 million acquisition of Viralytics signals growing interest in oncolytic viruses as potential enhancers for cancer immunotherapy treatments. - With 10 oncolytic viruses in clinical development and 40 in labs, these agents show promise in 'priming' tumors for checkpoint inhibitor therapy, potentially improving response rates. - Targovax emerges as a leading independent biotech in the oncolytic virus space, developing TG01 for pancreatic cancer and ONCOS-102 for mesothelioma in partnership with AstraZeneca's MedImmune.
